HCC2157

HCC2157

收藏
  • 询价
  • 2025年12月31日
    avatar
    14金牌会员
  • 企业认证

  • 万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 技术资料
    • 物种来源

    • 是否是肿瘤细胞

      1

    • 组织来源

      duct

    • 年限

      TNM stage IIIA, grade 2

    • 库存

      大量

    • 器官来源

      乳房

    • 运输方式

      冻存运输

    • 细胞形态

      上皮样

    • 相关疾病

      导管癌

    • ATCC Number

      CRL-2340™

    • 生长状态

      悬浮生长

    Designations: HCC2157
    Depositors:  AF Gazdar, AK Virmani
    Biosafety Level: 1
    Shipped: frozen
    Medium & Serum: See Propagation
    Growth Properties: suspension, multicell aggregates, Cells in suspension show an inclination to form duct-like structures and gland-like structures.
    Organism: Homo sapiens
    Morphology: epithelial

    Source: Organ: mammary gland; breast
    Tissue: duct
    Tumor Stage: TNM stage IIIA, grade 2
    Disease: primary ductal carcinoma
    Cellular Products: Epithelial glycoprotein 2 [EGP2]; cytokeratin 19
    Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
    Restrictions: The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.
    Applications: HCC2157 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
    The cells are negative for expression of estrogen receptor (ER -), but positive for expression of progesterone receptor (PR +).
    The cells are positive for expression of Her2-neu and for expression of p53.
    The cells form ducts and morula-like structures (hollow spherical structures lined with a single layer of cells).
    Receptors: estrogen receptor, negative
    progesterone receptor, positive
    Oncogene: her2/neu +, p53 +
    DNA Profile (STR): Amelogenin: X
    CSF1PO: 10
    D13S317: 12
    D16S539: 11
    D5S818: 13
    D7S820: 10,12
    THO1: 8,9
    TPOX: 9,11
    vWA: 14,18
    Cytogenetic Analysis: Number of cells examined = 59; Modal Chromosome Number = 75 with a range of 65 to 79; Polyploidy Rate = 22%
    Age: 48 years adult
    Gender: female
    Ethnicity: Black
    Comments: This cell line was initiated on 3/4/96 and took 8 months to establish.
    The tumor was classified as TNM stage IIIA, grade 2, ductal carcinoma with 1 out of 9 lymph node metastasis.
    The cells form ducts and morula-like structures (hollow spherical structures lined with a single layer of cells).
    The cells are positive for expression of Her2-neu and for expression of p53.
    HCC2157 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
    The cells are negative for expression of estrogen receptor (ER -), but positive for expression of progesterone receptor (PR +).
    An EBV transformed lymphoblastoid cell line (HCC2157 BL) from the same patient is available as ATCC CRL-2341 .
    Propagation: ATCC complete growth medium: ACL-4 medium supplemented with 10% FBS
    The base medium for this cell line is ATCC-formulated DMEM: F12 Medium Catalog No. 30-2006. To make the complete growth medium, add the following components to the base medium:
    1. 0.02 mg/ml insulin
    2. 0.01 mg/ml transferrin
    3. 25 nM sodium selenite
    4. 50 nM Hydrocortisone
    5. 1 ng/ml Epidermal Growth Factor (do not filter)
    6. 0.01 mM ethanolamine
    7. 0.01 mM phosphorylethanolamine
    8. 100 pM triiodothyronine
    9. 0.5% (w/v) bovine serum albumin
    10. 10 mM HEPES
    11. 0.5 mM sodium pyruvate
    12. 2mM L-glutamine(for final conc. of 4.5 mM)
    13. 10% FBS

    Temperature: 37.0°C
    Atmosphere: air, 95%; carbon dioxide (CO2), 5%
    Subculturing: Protocol: Cultures can be maintained by addition of fresh medium. Cultures grow as floating aggregates of large irregular cell clusters.
    Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
    Preservation: Freeze medium: Complete growth medium, 95%; DMSO, 5%
    Storage temperature: liquid nitrogen vapor temperature
    Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2006
    recommended serum:ATCC 30-2020
    Medium additive:ATCC 30-2214
    derived from same individual:ATCC CRL-2341
    References: 38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥500
    北京百奥创新科技有限公司
    2025年07月11日询价
    询价
    ATCC细胞库
    2025年08月24日询价
    ¥680
    上海联迈生物工程有限公司
    2025年08月25日询价
    ¥800
    上海康朗生物科技有限公司
    2025年07月15日询价
    询价
    上海莼试生物技术有限公司
    2025年10月26日询价
    HCC2157
    询价